Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores

This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to...

Descripción completa

Detalles Bibliográficos
Autores principales: Adhoute, Xavier, Wolf, Thomas
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701464/
https://www.ncbi.nlm.nih.gov/pubmed/35819258
http://dx.doi.org/10.1002/hep4.2047
_version_ 1784839540825915392
author Adhoute, Xavier
Wolf, Thomas
author_facet Adhoute, Xavier
Wolf, Thomas
author_sort Adhoute, Xavier
collection PubMed
description This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to be defined.[Image: see text]
format Online
Article
Text
id pubmed-9701464
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-97014642022-11-28 Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores Adhoute, Xavier Wolf, Thomas Hepatol Commun Correspondence This new UHPI score identifies three groups with different prognosis, but with no clear therapeutic guidance. Moreover, this model's predictive ability is now challenged in the era of combination therapies where durable responses are more commonly observed, and where response criteria remain to be defined.[Image: see text] John Wiley and Sons Inc. 2022-07-12 /pmc/articles/PMC9701464/ /pubmed/35819258 http://dx.doi.org/10.1002/hep4.2047 Text en © 2022 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Correspondence
Adhoute, Xavier
Wolf, Thomas
Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
title Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
title_full Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
title_fullStr Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
title_full_unstemmed Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
title_short Response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
title_sort response to immunotherapy plus anti‐angiogenic agent combination challenges hepatocellular carcinoma prognostic scores
topic Correspondence
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9701464/
https://www.ncbi.nlm.nih.gov/pubmed/35819258
http://dx.doi.org/10.1002/hep4.2047
work_keys_str_mv AT adhoutexavier responsetoimmunotherapyplusantiangiogenicagentcombinationchallengeshepatocellularcarcinomaprognosticscores
AT wolfthomas responsetoimmunotherapyplusantiangiogenicagentcombinationchallengeshepatocellularcarcinomaprognosticscores

Ejemplares similares